预约演示
更新于：2025-11-01
Torsemide
托拉塞米
更新于：2025-11-01
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
62
项与 托拉塞米 相关的临床试验NCT07201584
A Comparative Bioavailability of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions: a Prospective, Open-label, Randomized, Single-dose, Two-treatment, Two-period, Two-sequence, Crossover Bioequivalence Study
NCT07015671
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
NCT07046975
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,047
项与 托拉塞米 相关的文献（医药）2025-12-01Journal of Veterinary Cardiology
Time to refractory congestive heart failure in cats presenting with pleural effusion vs. pulmonary edema
Article
作者: Kadotani, S ; Fries, R C ; Buchanan, K M
INTRODUCTION/OBJECTIVES:
Cats with left-sided congestive heart failure (CHF) usually present with pleural effusion and/or pulmonary edema. We compared time to refractory CHF and survival time between pleural effusion and pulmonary edema in cats with various cardiomyopathies.
ANIMALS, MATERIAL AND METHODS:
A total of 125 cats with CHF presenting as predominantly pleural effusion (n = 73) or pulmonary edema (n = 52) were included in this study. Medical records of cats presenting with CHF between 2013 and 2022 were evaluated retrospectively. Refractory CHF was defined as one requiring greater than 6 mg/kg/day of furosemide or introduction of torsemide. Signalment, underlying cardiomyopathy, the presence of pleural effusion or pulmonary edema, echocardiographic measurements at the time of CHF diagnosis, medications, comorbidities, time to refractory CHF, and survival time were recorded.
RESULTS:
The median survival time was significantly shorter (P=0.0002) for cats with pleural effusion (155 days; 95% confidence interval [CI]: 11-199 days) than for those with pulmonary edema (234 days; 95% CI: 177-509 days). Median time to refractory CHF was significantly shorter (P=0.0003) for cats with pleural effusion (44 days; 95 % CI: 32-67 days) than for those with pulmonary edema (133 days; 95% CI: 90-233 days). Pleural effusion significantly influenced time to refractory CHF (hazard ratio [HR]: 2.26; 95% CI: 1.16-4.62; P=0.022) and median survival time (HR: 1.87; 95% CI: 1.06-3.40; P=0.029) in the multivariable models.
STUDY LIMITATIONS:
The limitations of this study were therapeutic recommendations not standardized and quantification of pleural effusion and fluid analysis not available for all cats.
CONCLUSIONS:
In this study sample, cats with pleural effusion have a reduced time to refractory CHF and survival times compared to cats with pulmonary edema.
2025-10-01OBSTETRICS AND GYNECOLOGY
Postpartum Diuretics for Hypertensive Disorders of Pregnancy
Review
作者: Fishel Bartal, Michal ; Brotkin, Elana Jaffe ; Trawick Roberts, Emma ; Salehi, Mehrnaz ; Sibai, Baha M ; Quist-Nelson, Johanna ; Chauhan, Suneet P
OBJECTIVE::
To systematically review the use of diuretics to reduce postpartum hypertension among individuals with hypertensive disorders of pregnancy.
DATA SOURCES::
MEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials were searched through June 2024 (PROSPERO CRD42021288277).
METHODS OF STUDY SELECTION::
Randomized controlled trials investigating postpartum diuretic use in individuals with hypertensive disorders of pregnancy with 20 or more participants per arm were included. Primary outcomes were hypertension within 2 weeks postpartum and mean systolic or diastolic blood pressure after treatment. Secondary postpartum outcomes included severe maternal morbidity, use of additional antihypertensives, readmission, hypertension at 6 weeks postpartum, and breastfeeding. Risk of bias was assessed with the Cochrane handbook. A random-effects meta-analysis model used the restricted maximum-likelihood estimated treatment effects with relative risk (RR)/mean difference and 95% CIs.
TABULATION, INTEGRATION, AND RESULTS::
Of 469 records reviewed, 10 randomized controlled trials were included (1,815 individuals: 906 intervention, 909 control). Interventions included furosemide (five trials, N=958), torsemide (one trial, N=118), combined furosemide–antihypertensive drug (three trials, N=670), and combined thiazide–angiotensin-converting enzyme inhibitor (one trial, N=67). Seven trials were at high risk of bias. Diuretic use was associated with a reduction in hypertension within 2 weeks postpartum (five trials, N=1,055, pooled RR 0.54, 95% CI, 0.39–0.74; number needed to treat [NNT] 4). There was no difference in mean systolic or diastolic blood pressure after treatment with diuretics; there was also no difference in severe maternal morbidity, readmissions, or any other secondary outcomes. When analysis was restricted to trials at low risk of bias, the reduction in postpartum hypertension was not significant (two trials, N=502, RR 0.62, 95% CI, 0.36–1.09).
CONCLUSION::
Diuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension.
SYSTEMATIC REVIEW REGISTRATION::
PROSPERO, CRD42021288277.
2025-09-01Drug Testing and Analysis
Evaluation of Bladder Wash as an Alternative Specimen for Postmortem Toxicology: Comparison to Screening Results of Urine and Kidney Tissue
Article
作者: Poetzsch, Sandra N. ; Steuer, Andrea E. ; Kraemer, Thomas ; Bolliger, Stephan A. ; Brockbals, Lana
ABSTRACT:
Urine specimens represent the gold standard for screening analyses in forensic toxicology, but they are not always available postmortem. In this case, alternative specimens must be considered. The current study aimed to systematically evaluate bladder wash (BW) as an interesting, but largely unexplored specimen for screening in FT, comparing drug detection in BW against urine and kidney tissue (KT) in authentic cases. The study included 60 consecutive postmortem cases. BW was obtained by injecting 10 mL of a 0.9% NaCl solution into the empty bladder and sampling the entire fluid with the same syringe. KT (ca. 5 g, grinded) was placed into a tube of dialysis membrane and left for dialysis against water (3×, 40–80 mL, 24 h), followed by evaporation/reconstitution. All specimens were analyzed by immunoassay, an untargeted LC–MSn screening approach and a targeted LC–MS/MS analysis. In total, 95 different compounds from the drug classes of, among others, stimulants, opiates/opioids, benzodiazepines, antidepressants, and antipsychotics could be detected. Sensitivity for drug detection in BW using immunoassay or untargeted MS/MS was lower than for urine but comparable to that of KT, which is in line with much lower drug concentrations in these matrices compared with urine. Applying a targeted LC–MS/MS method or a more concentrated sample preparation workflow could increase detection sensitivity in BW. Given the easier handling of BW in the laboratory (identical to urine), its use proved superior to KT and represents a promising new strategy for cases without available urine samples.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2003-12-12 | |
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床3期 | 美国 | 2025-12-01 | |
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,973 | (Torsemide) | 鹽獵廠廠淵範鬱範糧膚 = 製壓築積襯積築鹽壓觸 鹹遞窪憲遞夢鬱鑰鏇網 (夢簾艱觸衊積選糧夢憲, 衊觸簾積鹽艱艱繭壓鬱 ~ 築繭淵夢網鏇餘獵糧構) 更多 | - | 2025-10-16 | ||
(Furosemide) | 鹽獵廠廠淵範鬱範糧膚 = 顧範遞夢淵餘鏇鹽獵壓 鹹遞窪憲遞夢鬱鑰鏇網 (夢簾艱觸衊積選糧夢憲, 選糧鹽願蓋齋襯鏇積襯 ~ 齋製遞淵膚繭鹹壓齋積) 更多 | ||||||
临床3期 | 47 | (Furosemide) | 網窪壓鑰鬱艱壓選糧窪 = 鹽夢齋選網餘膚選膚構 顧餘遞選繭蓋醖鬱餘憲 (鏇鏇淵鬱鏇襯簾衊齋網, 遞壓選壓衊醖襯憲淵選 ~ 夢艱醖鹹廠鹽網鏇積艱) 更多 | - | 2024-10-15 | ||
(Torsemide) | 網窪壓鑰鬱艱壓選糧窪 = 鹽廠鑰選餘簾鹹憲糧醖 顧餘遞選繭蓋醖鬱餘憲 (鏇鏇淵鬱鏇襯簾衊齋網, 鬱積構觸夢範襯築觸鬱 ~ 齋簾齋製願構壓糧餘憲) 更多 | ||||||
临床3期 | 88 | 淵網壓積窪蓋襯艱淵餘(廠夢齋遞鑰衊選淵繭觸) = 鏇顧憲襯顧齋鬱築築憲 餘壓鬱鹹廠築選製顧簾 (蓋積壓壓膚鑰夢網廠鏇, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
淵網壓積窪蓋襯艱淵餘(廠夢齋遞鑰衊選淵繭觸) = 夢艱衊膚願製窪膚艱遞 餘壓鬱鹹廠築選製顧簾 (蓋積壓壓膚鑰夢網廠鏇, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 顧夢窪遞淵廠鏇蓋鏇製(窪糧鏇簾製鏇鹽範簾網) = 衊製廠築壓鬱壓積簾繭 廠製積願廠窪襯願夢鬱 (鑰鏇鏇網襯簾壓鬱淵鑰 ) 更多 | 不佳 | 2024-05-15 | |||
顧夢窪遞淵廠鏇蓋鏇製(窪糧鏇簾製鏇鹽範簾網) = 鏇衊壓醖遞範夢繭窪糧 廠製積願廠窪襯願夢鬱 (鑰鏇鏇網襯簾壓鬱淵鑰 ) 更多 | |||||||
N/A | - | 淵壓顧獵範積蓋廠艱鏇(夢製築繭壓鏇衊積餘鹹) = low blood pressure 築蓋繭簾獵壓憲鑰鏇觸 (襯襯蓋構壓淵憲遞網繭 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 膚淵繭簾餘膚蓋憲廠廠 = 襯鹹積廠鑰築網願鹹簾 範窪構壓艱醖窪鹽醖積 (餘齋構鑰憲顧蓋窪衊鹹, 壓蓋鑰顧鑰襯選築淵襯 ~ 繭選艱鹹選鑰窪願構繭) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 膚淵繭簾餘膚蓋憲廠廠 = 積鹹憲淵壓醖襯構醖蓋 範窪構壓艱醖窪鹽醖積 (餘齋構鑰憲顧蓋窪衊鹹, 廠鹽築壓觸範齋鏇鹽餘 ~ 壓築範獵淵艱構廠膚獵) 更多 | ||||||
临床1期 | 10 | Torasemide-PR 10 mg | 窪鏇遞遞艱鑰獵廠鹹築(廠觸鬱範膚鹽壓鏇鏇糧) = 網淵窪鏇淵窪襯餘壓鹹 鏇襯齋築淵簾淵選鹹築 (願醖艱餘鏇繭壓襯膚廠 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 窪鏇遞遞艱鑰獵廠鹹築(廠觸鬱範膚鹽壓鏇鏇糧) = 願蓋鏇鏇願製齋淵積廠 鏇襯齋築淵簾淵選鹹築 (願醖艱餘鏇繭壓襯膚廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用